Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CGEN NASDAQ:GLSI NASDAQ:KYTX OTCMKTS:SEOVF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGENCompugen$1.59-5.9%$1.57$1.13▼$2.66$141.89M2.57364,387 shs329,117 shsGLSIGreenwich LifeSciences$10.84-3.4%$9.61$8.06▼$17.00$144.93M1.6343,933 shs60,219 shsKYTXKyverna Therapeutics$4.03+12.9%$2.78$1.78▼$11.40$174.18M2.95385,234 shs826,134 shsSEOVFSernova Biotherapeutics$0.12+2.7%$0.13$0.10▼$0.25$39.75M113,569 shs42,000 shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGENCompugen0.00%-10.67%-3.05%+21.37%-9.66%GLSIGreenwich LifeSciences0.00%+8.02%+17.83%+16.81%-30.65%KYTXKyverna Therapeutics0.00%+39.21%+25.16%+80.72%-58.84%SEOVFSernova Biotherapeutics0.00%+11.21%-3.82%-4.35%-42.63%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCGENCompugen1.6149 of 5 stars3.52.00.00.02.70.00.0GLSIGreenwich LifeSciences2.1759 of 5 stars3.50.00.00.03.33.30.0KYTXKyverna Therapeutics2.0199 of 5 stars3.62.00.00.02.60.00.6SEOVFSernova BiotherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCGENCompugen 3.00Buy$4.00151.57% UpsideGLSIGreenwich LifeSciences 3.00Buy$39.00259.78% UpsideKYTXKyverna Therapeutics 3.14Buy$18.50359.06% UpsideSEOVFSernova Biotherapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest SEOVF, KYTX, CGEN, and GLSI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025KYTXKyverna TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$4.00 ➝ $5.004/21/2025GLSIGreenwich LifeSciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$38.00 ➝ $39.00(Data available from 7/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCGENCompugen$27.86M5.09N/AN/A$0.62 per share2.56GLSIGreenwich LifeSciencesN/AN/AN/AN/A$0.19 per shareN/AKYTXKyverna Therapeutics$7.03M24.78N/AN/A$6.17 per share0.65SEOVFSernova BiotherapeuticsN/AN/AN/AN/A($0.03) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCGENCompugen-$14.23M-$0.16N/AN/AN/A-51.27%-24.51%-12.19%8/5/2025 (Estimated)GLSIGreenwich LifeSciences-$15.79M-$1.26N/AN/AN/AN/A-450.87%-333.18%8/12/2025 (Estimated)KYTXKyverna Therapeutics-$127.48M-$3.38N/AN/AN/AN/A-51.66%-45.92%8/11/2025 (Estimated)SEOVFSernova Biotherapeutics-$23.65M-$0.04N/A∞N/AN/AN/A-396.49%9/15/2025 (Estimated)Latest SEOVF, KYTX, CGEN, and GLSI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025KYTXKyverna Therapeutics-$1.00N/AN/AN/AN/AN/A8/5/2025Q2 2025CGENCompugen-$0.07N/AN/AN/A$3.95 millionN/A6/13/2025Q2 2025SEOVFSernova BiotherapeuticsN/A-$0.01N/A-$0.01N/AN/A5/20/2025Q1 2025GLSIGreenwich LifeSciences-$0.24-$0.25-$0.01-$0.25N/AN/A5/19/2025Q1 2025CGENCompugen-$0.06-$0.08-$0.02-$0.08$3.70 million$2.28 million5/13/2025Q1 2025KYTXKyverna Therapeutics-$1.21-$1.03+$0.18-$1.03N/AN/A4/15/2025Q4 2024GLSIGreenwich LifeSciences-$0.21-$0.61-$0.40-$0.61N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCGENCompugenN/AN/AN/AN/AN/AGLSIGreenwich LifeSciencesN/AN/AN/AN/AN/AKYTXKyverna TherapeuticsN/AN/AN/AN/AN/ASEOVFSernova BiotherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCGENCompugenN/A5.095.09GLSIGreenwich LifeSciencesN/A1.911.91KYTXKyverna TherapeuticsN/A7.447.44SEOVFSernova BiotherapeuticsN/A0.120.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCGENCompugen12.22%GLSIGreenwich LifeSciences4.16%KYTXKyverna Therapeutics18.08%SEOVFSernova BiotherapeuticsN/AInsider OwnershipCompanyInsider OwnershipCGENCompugen9.50%GLSIGreenwich LifeSciences51.67%KYTXKyverna TherapeuticsN/ASEOVFSernova BiotherapeuticsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCGENCompugen7089.24 million80.76 millionOptionableGLSIGreenwich LifeSciences313.37 million6.46 millionNot OptionableKYTXKyverna Therapeutics9643.22 millionN/AOptionableSEOVFSernova BiotherapeuticsN/A328.49 millionN/ANot OptionableSEOVF, KYTX, CGEN, and GLSI HeadlinesRecent News About These CompaniesSernova Biotherapeutics Announces Collaboration with Eledon ...July 11 at 11:47 AM | morningstar.comMSernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals to Advance a Potential Functional Cure for Type 1 DiabetesJuly 9, 2025 | globenewswire.comSernova Biotherapeutics Taps CEO to Be Interim ChairJune 2, 2025 | marketwatch.comSernova Appoints Jonathan Rigby as Interim ChairJune 2, 2025 | globenewswire.comChair of Sernova Biotherapeutics ResignsMay 25, 2025 | globenewswire.comSernova Biotherapeutics Appoints World-Class Clinical Advisory Board to Support Development of Cell Pouch Bio-hybrid Organ as Functional Cure for Type 1 DiabetesMay 22, 2025 | globenewswire.comSernova Biotherapeutics Provides Positive Interim Data from Ongoing Phase 1/2 Clinical Trial of Cell Pouch Bio-hybrid Organ in Patients Living with Type 1 DiabetesMay 14, 2025 | globenewswire.comSernova Biotherapeutics Secures $4 Million Loan to Further Advance its Clinical Development PlansApril 17, 2025 | globenewswire.comSernova Biotherapeutics Cell Pouch Bio-hybrid Organ to be Highlighted at Cell & Gene Meeting on the MedApril 15, 2025 | globenewswire.comSernova Biotherapeutics Provides Update on Phase 1/2 Clinical Trial of Cell Pouch™ Bio-Hybrid Organ for Treatment of Type 1 DiabetesApril 1, 2025 | globenewswire.comSernova names Pericles Calias as CDO and head of R&DMarch 11, 2025 | thepharmaletter.comTSernova Biotherapeutics Appoints Pericles Calias, Ph.D. as Chief Development Officer and Head of R&DMarch 10, 2025 | globenewswire.comSernova Biotherapeutics Secures $1 Million Convertible Debt FinancingMarch 5, 2025 | globenewswire.comSernova Biotherapeutics Receives FDA Clearance for IND Application for its Cell Pouch Bio-hybrid Organ with Autograft Thyroid Cells in Patients with HypothyroidismMarch 3, 2025 | globenewswire.comSernova Biotherapeutics Submits IND Application for its Cell Pouch Bio-Hybrid Organ with Autograft Thyroid Cells in Patients with HypothyroidismFebruary 3, 2025 | globenewswire.comSernova Corp. Shareholders Approve Key Resolutions at Annual MeetingJanuary 14, 2025 | tipranks.comSernova Advances Diabetes Cure with Strategic InitiativesJanuary 14, 2025 | tipranks.comSernova Financial joins FIA Tech’s Databank NetworkJanuary 13, 2025 | finextra.comFSernova Announces Voting Results from its Annual and Special General Meeting of ShareholdersJanuary 13, 2025 | finance.yahoo.comSernova Reschedules its Annual General and Special Meeting of Shareholders to January 10, 2025December 20, 2024 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSEOVF, KYTX, CGEN, and GLSI Company DescriptionsCompugen NASDAQ:CGEN$1.59 -0.10 (-5.92%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$1.66 +0.06 (+4.09%) As of 07:56 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.Greenwich LifeSciences NASDAQ:GLSI$10.84 -0.38 (-3.39%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$10.82 -0.02 (-0.14%) As of 07/11/2025 06:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.Kyverna Therapeutics NASDAQ:KYTX$4.03 +0.46 (+12.89%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$4.06 +0.03 (+0.74%) As of 08:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.Sernova Biotherapeutics OTCMKTS:SEOVF$0.12 +0.00 (+2.72%) As of 07/11/2025 02:45 PM EasternSernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a novel implantable and scalable medical device which forms a natural environment in the body for the housing and long-term survival and function of therapeutic cells, which release necessary proteins or factors missing from the body to treat chronic diseases as an alternative to daily administration of drugs. Sernova Corp. has a research agreement with the University of Miami to advance the development of Conformal Coating Technology in combination with therapeutic cells within Cell Pouch. Sernova Corp. was incorporated in 1998 and is headquartered in London, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/07 - 07/11 Power Solutions International Poised for 75% Upside The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? 3 Catalysts Converge on Intel Ahead of a Critical Earnings Report Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Conagra at Rock Bottom: 7% Yield & Turnaround Poised Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
